Altimmune's Liver Drug Moves Closer to the Finish Line

Altimmune confirms a 2026 Phase 3 launch for pemvidutide, backed by FDA Breakthrough Therapy status and $340M in capital

6 Mar 2026

The race to treat one of medicine's most persistent liver diseases just got more serious. Altimmune has confirmed a 2026 Phase 3 launch for pemvidutide, its investigational drug for MASH, riding a wave of regulatory momentum and a freshly secured $340 million capital base to fund the pivotal trial.

MASH, or metabolic dysfunction-associated steatohepatitis, is no ordinary condition. It causes fat to accumulate in the liver, sparking inflammation and scarring that can quietly progress to cirrhosis or outright liver failure. Effective treatments have long been scarce, but that is beginning to change.

What sets pemvidutide apart is its dual-receptor design. It activates glucagon receptors to tackle liver fat, inflammation, and fibrosis directly, while GLP-1 receptor engagement drives broader benefits like appetite suppression and weight loss. The result is a drug that goes after MASH from two biological angles at once.

The FDA's Breakthrough Therapy Designation, granted in January 2026, was no small nod. It came on the strength of 24-week Phase 2b data showing statistically significant MASH resolution without worsening fibrosis, and it unlocks intensive agency guidance throughout development. A second boost arrived in December 2025, when 48-week data from the same trial reinforced the case for pressing forward.

Altimmune laid out the Phase 3 plan alongside its full-year 2025 financials on March 5, 2026. The trial will test multiple doses over 52 weeks using biopsy-based endpoints, the gold standard for measuring real change in liver tissue. The company also holds FDA Fast Track Designation for both MASH and alcohol use disorder, broadening pemvidutide's potential beyond a single indication.

With funding in place, a clear regulatory path, and two rounds of encouraging clinical data behind it, Altimmune is well-positioned heading into its most consequential test yet. For patients living with a disease that has too often been met with a shrug, the progress is long overdue.